Johnson & Johnson, Crucell biotech announce takeover

October 6, 2010

Pharmaceutical and health care giant Johnson & Johnson has reached a deal with Dutch biotechnology vaccine group Crucell to buy 82.5 percent of Crucell for about 1.75 billion euros, the two firms said on Wednesday.

The payment, in cash for the equivalent of 2.4 billion dollars), would be made by a subsidiary of Johnson & Johnson which already owns 17.5 percent of the biotechnology firm.

The head of pharmaceutical research at Johnson & Johnson, Paul Stoffels, said: "This potential combination would provide us with a new platform for growth and advances our goal to deliver integrated health care solutions, with particular emphasis on prevention."

The price represents 24.75 euros per share, and a premium of 58 percent from the price on September 16, the day before the two groups revealed that they were in advanced talks. The price represents a premium of 63 percent on the average price in the previous 30 days.

Crucell, which employs 1,300 people, produced more than 115 million doses of vaccine last year for distribution in about 100 countries most of which are developing countries.

Johnson & Johnson, which employs 114,000 people, said it intended to retain the management and staff at Crucell and to keep the headquarters at Leiden in the west of the Netherlands.

Explore further: Summer time and the living is breezy

Related Stories

Summer time and the living is breezy

June 6, 2006

The U.S. hurricane season is under way and for many people in areas hit hard by 2005's hurricanes, it's going to be an uneasy summer.

Hormone therapy associated with reduced colorectal cancer risk

January 8, 2009

The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published ...

Johnson & Johnson plans to buy Dutch vaccine group

September 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.